Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Autor: Diaz Rohena, Daisy, Peris Cuesta, Arnau, Slawin, Bailey, Ravikrishnan, Janani, Liu, Chaomei, Williams, Charmelle, Hu, Wanyi, Zhang, Peiyi, Thompson, Philip, Wierda, William G., Jain, Nitin, Shukla, Sachet, Zheng, Guangrong, Zhou, Daohong, Woyach, Jennifer A., Sampath, Deepa

Publikováno v: In Blood 2 November 2023 142 Supplement 1:4195-4195

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Autor: Diaz Rohena, Daisy ^*, Slawin, Bailey ^*, Ravikrishnan, Janani, Liu, Chaomei ^*, Hu, Wanyi ^*, Zhang, Peiyi ^*, Thompson, Philip A., Wierda, William G., Jain, Nitin, Zheng, Guangrong ^*, Zhou, Daohong, Woyach, Jennifer A., Sampath, Deepa

Publikováno v: In Blood 15 November 2022 140 Supplement 1:497-498

Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax

Autor: Ravikrishnan, Janani, Muhowski, Elizabeth M., Lai, Tzung-Huei, Misra, Shrilekha, Diaz Rohena, Daisy, Tan, Felai, Chen, Yi, Anthony, Stephen P., Chen, Yu, Shen, Yue, Byrd, John C., Sampath, Deepa, Woyach, Jennifer A.

Publikováno v: In Blood 23 November 2021 138 Supplement 1:679-679

LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.

Autor: Ravikrishnan J; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Diaz-Rohena DY; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Muhowski E; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Mo X; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH., Lai TH; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Misra S; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Williams CD; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Sanchez J; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Mitchell A; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Satpati S; Department of Genomic Medicine, MD Anderson Cancer Center, Houston TX., Perry E; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Kaufman T; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Liu C; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Lozanski A; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Lozanski G; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Rogers K; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Kittai AS; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Bhat SA; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Collins MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jain N; Department of Leukemia, MD Anderson Cancer Center, Houston TX., Wierda WG; Department of Leukemia, MD Anderson Cancer Center, Houston TX., Lapalombella R; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Byrd JC; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH., Tan F; Newave Pharmaceutical Inc., Pleasanton, CA., Chen Y; Newave Pharmaceutical Inc., Pleasanton, CA., Chen Y; Newave Pharmaceutical Inc., Pleasanton, CA., Shen Y; Newave Pharmaceutical Inc., Pleasanton, CA., Anthony SP; Newave Pharmaceutical Inc., Pleasanton, CA., Woyach JA; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH. Jennifer.Woyach@osumc.edu., Sampath D; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX. DSampath@mdanderson.org.

Publikováno v: Haematologica [Haematologica] 2024 Aug 08. Date of Electronic Publication: 2024 Aug 08.